These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 32417852)

  • 1. Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine.
    Chen BK; Luna VM; LaGamma CT; Xu X; Deng SX; Suckow RF; Cooper TB; Shah A; Brachman RA; Mendez-David I; David DJ; Gardier AM; Landry DW; Denny CA
    Neuropsychopharmacology; 2020 Aug; 45(9):1545-1556. PubMed ID: 32417852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine.
    Shaffer CL; Dutra JK; Tseng WC; Weber ML; Bogart LJ; Hales K; Pang J; Volfson D; Am Ende CW; Green ME; Buhl DL
    Neuropharmacology; 2019 Jul; 153():73-81. PubMed ID: 31015046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidepressant-relevant concentrations of the ketamine metabolite (2
    Lumsden EW; Troppoli TA; Myers SJ; Zanos P; Aracava Y; Kehr J; Lovett J; Kim S; Wang FH; Schmidt S; Jenne CE; Yuan P; Morris PJ; Thomas CJ; Zarate CA; Moaddel R; Traynelis SF; Pereira EFR; Thompson SM; Albuquerque EX; Gould TD
    Proc Natl Acad Sci U S A; 2019 Mar; 116(11):5160-5169. PubMed ID: 30796190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression.
    Yokoyama R; Higuchi M; Tanabe W; Tsukada S; Naito M; Yamaguchi T; Chen L; Kasai A; Seiriki K; Nakazawa T; Nakagawa S; Hashimoto K; Hashimoto H; Ago Y
    Pharmacol Biochem Behav; 2020 Apr; 191():172876. PubMed ID: 32088360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex-dependent metabolism of ketamine and (
    Highland JN; Farmer CA; Zanos P; Lovett J; Zarate CA; Moaddel R; Gould TD
    J Psychopharmacol; 2022 Feb; 36(2):170-182. PubMed ID: 34971525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism.
    Riggs LM; Aracava Y; Zanos P; Fischell J; Albuquerque EX; Pereira EFR; Thompson SM; Gould TD
    Neuropsychopharmacology; 2020 Jan; 45(2):426-436. PubMed ID: 31216563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray.
    Chou D; Peng HY; Lin TB; Lai CY; Hsieh MC; Wen YC; Lee AS; Wang HH; Yang PS; Chen GD; Ho YC
    Neuropharmacology; 2018 Sep; 139():1-12. PubMed ID: 29953886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression.
    Zhao X; Venkata SL; Moaddel R; Luckenbaugh DA; Brutsche NE; Ibrahim L; Zarate CA; Mager DE; Wainer IW
    Br J Clin Pharmacol; 2012 Aug; 74(2):304-14. PubMed ID: 22295895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors.
    Moaddel R; Abdrakhmanova G; Kozak J; Jozwiak K; Toll L; Jimenez L; Rosenberg A; Tran T; Xiao Y; Zarate CA; Wainer IW
    Eur J Pharmacol; 2013 Jan; 698(1-3):228-34. PubMed ID: 23183107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketamine metabolite (2R,6R)-hydroxynorketamine enhances aggression via periaqueductal gray glutamatergic transmission.
    Ye L; Ko CY; Huang Y; Zheng C; Zheng Y; Chou D
    Neuropharmacology; 2019 Oct; 157():107667. PubMed ID: 31207251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chiral LC-MS/MS method for the simultaneous determination of (R,S)-ketamine, (R,S)-norketamine, and (2R,6R;2S,6S)-hydroxynorketamine in mouse plasma and brain.
    Toki H; Yamaguchi JI; Mizuno-Yasuhira A; Endo H
    J Pharm Biomed Anal; 2023 Feb; 224():115168. PubMed ID: 36473323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.
    Zanos P; Highland JN; Liu X; Troppoli TA; Georgiou P; Lovett J; Morris PJ; Stewart BW; Thomas CJ; Thompson SM; Moaddel R; Gould TD
    Br J Pharmacol; 2019 Jul; 176(14):2573-2592. PubMed ID: 30941749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of the sustained antidepressant-like effect of (2R,6R)-hydroxynorketamine in NMDA receptor GluN2D subunit knockout mice.
    Yamagishi A; Ikekubo Y; Mishina M; Ikeda K; Ide S
    J Pharmacol Sci; 2024 Mar; 154(3):203-208. PubMed ID: 38395521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subchronic administration of (R,S)-ketamine induces ketamine ring hydroxylation in Wistar rats.
    Moaddel R; Sanghvi M; Ramamoorthy A; Jozwiak K; Singh N; Green C; O'Loughlin K; Torjman M; Wainer IW
    J Pharm Biomed Anal; 2016 Aug; 127():3-8. PubMed ID: 27017097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic (R,S)-ketamine and (2S,6S)-hydroxynorketamine Decrease Fear Expression by Differentially Modulating Fear Neural Ensembles.
    Mastrodonato A; Jin M; Kee N; Lanio M; Tapia J; Quintana L; Muñoz Zamora A; Deng SX; Xu X; Landry DW; Denny CA
    Biol Psychiatry; 2024 Oct; ():. PubMed ID: 39389408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit.
    Yao N; Skiteva O; Zhang X; Svenningsson P; Chergui K
    Mol Psychiatry; 2018 Oct; 23(10):2066-2077. PubMed ID: 29158578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Pharmacological Evaluation of the Analgesic Effect and Hippocampal Protein Modulation of the Ketamine Metabolite (2R,6R)-Hydroxynorketamine in Murine Pain Models.
    Das V; Basovich MB; Thomas CJ; Kroin JS; Buvanendran A; McCarthy RJ
    Anesth Analg; 2024 May; 138(5):1094-1106. PubMed ID: 37319016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (
    Zanos P; Highland JN; Stewart BW; Georgiou P; Jenne CE; Lovett J; Morris PJ; Thomas CJ; Moaddel R; Zarate CA; Gould TD
    Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6441-6450. PubMed ID: 30867285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2
    Fukumoto K; Fogaça MV; Liu RJ; Duman C; Kato T; Li XY; Duman RS
    Proc Natl Acad Sci U S A; 2019 Jan; 116(1):297-302. PubMed ID: 30559184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antinociceptive and Analgesic Effects of (2
    Yost JG; Wulf HA; Browne CA; Lucki I
    J Pharmacol Exp Ther; 2022 Sep; 382(3):256-265. PubMed ID: 35779947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.